Clin Infect Dis by Salvadori, Nicolas et al.
Maternal and Infant Bone Mineral Density 1 Year After Delivery in 
a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil 
Fumarate to Prevent Mother-to-child Transmission of Hepatitis B 
Virus
Nicolas Salvadori1,2, Bo Fan3, Waralee Teeyasoontranon4, Nicole Ngo-Giang-Huong1,2,5, 
Siriluk Phanomcheong6, Anita Luvira7, Achara Puangsombat8, Arunrat Suwannarat9, 
Ussanee Srirompotong10, Chaiwat Putiyanun11, Tim R. Cressey1,2,5,12, Luc Decker1,2, 
Woottichai Khamduang2, Linda Harrison13, Camlin Tierney13, John A. Shepherd3,14, 
Athena P. Kourtis15, Marc Bulterys15,16, George K. Siberry17, and Gonzague Jourdain1,2,5
1Institut de Recherche pour le Développement (IRD)-PHPT, Chiang Mai University, Thailand 
2Faculty of Associated Medical Sciences, Chiang Mai University, Thailand 3Department of 
Radiology and Biomedical Imaging, University of California–San Francisco 4Department of 
Radiology, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, 
Thailand 5Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of 
Public Health, Boston, Massachusetts 6Banglamung Hospital, Chon Buri, Thailand 7Nopparat 
Rajathanee Hospital, Bangkok, Thailand 8Samutprakarn Hospital, Samut Prakan, Thailand 
9Nakornping Hospital, Chiang Mai, Thailand 10Khon Kaen Hospital, Thailand 11Chiang Kham 
Hospital, Thailand 12Department of Molecular and Clinical Pharmacology, Institute of Translational 
Medicine, University of Liverpool, United Kingdom 13Center for Biostatistics in AIDS Research, 
Harvard T.H. Chan School of Public Health, Boston, Massachusetts 14Population Sciences in the 
Pacific Program, University of Hawaii Cancer Center, Honolulu 15Centers for Disease Control and 
Prevention, Atlanta, Georgia 16Department of HIV/Hepatitis, WHO Global Hepatitis Programme, 
Geneva, Switzerland 17Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, National Institutes of Health, Bethesda, Maryland
Abstract
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use 
from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of 
hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone 
mineral density 1 year after delivery/birth.
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Tenofovir disoproxil fumarate (TDF) is increasingly prescribed for the prevention of mother-
to-child transmission (PMTCT) of hepatitis B virus (HBV) [1]. Maternal TDF use during 
pregnancy and lactation may adversely affect both maternal and infant bone mineral density 
(BMD) as seen in human immunodeficiency virus (HIV)–infected infants [2]. However, 
concomitant antiretroviral drugs, HIV infection, or related inflammation may also play a 
role. We report the results of a secondary endpoint analysis of a randomized, controlled trial 
assessing the effect of maternal TDF use vs placebo on maternal and infant BMD 1 year 
after delivery/birth in HBV-infected and HIV-uninfected mothers and their infants.
METHODS
Population and Design
The iTAP study was a randomized, double-blind, multicenter clinical trial where women 
with chronic HBV infection received TDF or a matching placebo from 28 weeks gestational 
age (GA) to 2 months postpartum in Thailand [3]. The results of the primary efficacy and 
safety endpoints have been published [4]. Following an amendment to the protocol, starting 
on 1 July 2015, all mothers and their infants were invited to participate in a BMD 
assessment 12 months after delivery/birth (±1.5 months).
Settings and Procedures
Consenting women and their infants were referred to 1 of 3 participating sites for dual-
energy X-ray absorptiometry (DXA) assessments using Hologic Discovery A (Hologic, Inc., 
Marlborough, MA). After maternal consent, maternal hip and lumbar spine BMD and infant 
lumbar spine BMD were measured 12 months after delivery/birth. No more than 3 attempts 
were made to acquire a valid hip or spine scan. A DXA specialist (B. F.) circulated the 
phantoms to each of the participating sites for cross-calibration, trained the operators, and 
performed a precision study on the first 5 mother and infant scans collected at each site. The 
DXA scans were centrally analyzed using software version APEX 4.0.2 by a second DXA 
specialist (W. T.). Participants, investigators, operators, and DXA specialists remained 
blinded to the study treatment arm during the BMD assessment study.
Statistical Considerations
The main outcome measures were the total hip BMD in mothers and the lumbar spine BMD 
in both mothers and infants, expressed in grams per square centimeter. The total hip BMD 
was calculated as the sum of the bone mineral content (BMC) measured at the femoral neck, 
trochanter, and intertrochanter divided by the sum of the area measured at each of these 3 
regions. The lumbar spine BMD was calculated as the sum of the BMC measured at L1, L2, 
L3, and L4 vertebrae divided by the sum of the area measured at each of these 4 vertebrae. 
Only scans with valid measurements in all areas were included in the analysis. Mean 
maternal total hip and lumbar spine BMD and infant lumbar spine BMD were compared 
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between TDF and placebo arms using a 2-sided Student t test. Assuming a mean (standard 
deviation) lumbar spine BMD of 0.312 g/cm2 (0.070 g/cm2) [5] in infants in the placebo 
arm, we calculated that a sample size of at least 45 mother–infant pairs per arm would 
provide more than 80% power to detect a mean difference of 0.042 g/cm2 in infant lumbar 
spine BMD in the TDF arm compared to the placebo arm, that is, a relative mean difference 
of 13.5% (2-sided Student t test, alpha = .05).
Ethical Considerations
The ethics committee of the Institute for the Development of Human Research Protections at 
the Ministry of Public Health (Thailand) and the ethics committees at the clinic sites 
approved the protocol.
RESULTS
Participants
Between July 2015 and October 2016, 140 mothers (71 TDF, 69 placebo) and 137 infants 
(70 TDF, 67 placebo) were included in the BMD assessment: 135 mother–infant pairs (69 
TDF, 66 placebo), 5 singleton mothers (2 TDF, 3 placebo), and 2 singleton infants (1 TDF, 1 
placebo). Reasons for exclusion among the 322 randomized mothers who delivered and their 
infants were the following: reached 12 months postpartum before protocol amendment (116 
mothers [59 TDF, 57 placebo], 116 infants [59 TDF, 57 placebo]), declined participation (65 
mothers [32 TDF, 33 placebo], 64 infants [31 TDF, 33 placebo]), could not come with their 
mothers (5 infants [2 TDF, 3 placebo]), and became newly pregnant (1 mother [placebo]).
At study treatment initiation (28 weeks GA), median maternal age was 26.7 years 
(interquartile range, 23.3 to 29.2), weight 62 kg (56 to 71), and HBV DNA 8.0 log10 IU/mL 
(7.3 to 8.4). At delivery, median GA was 39.1 weeks (38.3 to 40.1). Median breastfeeding 
duration was 6.1 months (3.8 to 12.0) for the 135 (96%) mothers who breastfed. BMD was 
assessed at a median 12.2 months (11.9 to 12.5) after delivery/birth. At this time, median 
maternal weight was 55 kg (50 to 62). Of the 137 infants, 69 (50%) were male. Median 
infant weight-for-age z score was −0.49 (−1.06 to 0.25) and length-for-age z score was 
−0.46 (−1.18 to 0.58) at the time of BMD assessment.
Except for maternal HBV DNA at delivery, participant characteristics in the 2 arms were 
similar (Supplementary Table 1).
Maternal and Infant BMD
The BMD measurements were valid for the hip in 129 mothers (64 TDF, 65 placebo) and for 
the lumbar spine in 138 mothers (71 TDF, 67 placebo) and 115 infants (62 TDF, 53 
placebo). Invalid measurements were due to movement or improper positioning.
There were no significant differences between TDF and placebo arms in maternal hip BMD 
(mean difference of +0.008 g/cm2 [95% confidence interval, −0.028 to +0.044 g/cm2]; P = .
67), maternal lumbar spine BMD (+0.010 g/cm2 [− 0.026 to +0.046 g/cm2]; P = .59), or 
infant lumbar spine BMD (−0.006 g/cm2 [−0.019 to +0.007 g/cm2]; P = .38) (Table 1). 
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Similar results were found in a sensitivity analysis excluding 2 HBV-infected infants from 
the placebo arm.
DISCUSSION
In this randomized trial for PMTCT of HBV where women received TDF or placebo from 
28 weeks GA to 2 months postpartum and breastfed their infants, we did not find significant 
evidence for an effect of maternal TDF use on maternal or infant BMD 1 year after delivery/
birth.
Postpartum maternal mean total hip and mean lumbar spine BMD in this Asian population 
seemed similar to that in white populations [6–8] taking into account the specificity of the 
previous studies in terms of proportion of breastfeeding mothers, duration of breastfeeding, 
and time of measurement after weaning [6, 9]. Infant mean lumbar spine BMD was similar 
to that reported in white and African American infants [5, 10].
There were no significant differences in BMD between arms, but it is possible that a deficit 
in bone mineralization might have occurred earlier in mothers on TDF and/or in infants 
during breastfeeding, although previous studies have reported conflicting results [2, 11]. All 
women of our population received TDF for the same duration (5 months) and, in contrast 
with these studies, were chronically infected with HBV and uninfected with HIV and 
therefore unexposed to any other antiretrovirals.
A strength of our study was that it provided information on the potential effect of TDF on 
BMD 1 year after delivery/birth in HBV monoinfected women and their infants. Indeed, the 
results of studies conducted in an HIV-monoinfected, HIV–HBV-coinfected or HBV-
monoinfected population should not be extrapolated to other populations.
A limitation of our study is that BMD was only measured at 1 year after delivery/birth. 
Earlier measurement time points would have provided information on the evolution of BMD 
in the 2 arms. Indeed, a progressive decrease in maternal BMD during breastfeeding with 
spontaneous compensation after weaning has been observed without TDF [6], and the role of 
TDF during this period remains unknown. Another limitation is that BMD assessment was 
performed in a subset of all women randomized to receive TDF or placebo. However, the 
double-blind aspect was maintained during the BMD assessment, and most participant 
characteristics were found to be similar between the 2 arms, suggesting a limited impact.
In conclusion, together with the absence of significant differences in infant growth 
parameters [12], TDF prophylaxis to prevent mother-to-child transmission of HBV in HBV-
monoinfected women in Asia appeared safe with regard to bone mineralization for both 
mothers and infants. This information will contribute to our knowledge regarding the safety 
of this approach [1].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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